Search the Newsreel

Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?

Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook to US$3.88 billion–US$3.93 billion. Alongside these results, BioMarin filed a …

Sei Investments Co. Sells 98,315 Shares of Intuitive Machines, Inc. $LUNR

Deutsche Bank upgrades PennyMac Mortgage stock rating on valuation

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant …

Dow Futures Slip, S&P 500, Nasdaq Futures Climb Ahead Of Key Retail Earnings, Fed Minutes: NLST, AVGO, LUNR, MRK Stocks In Focus

Can Retail Earnings Keep S&P 500 Rally Alive? NLST, AVGO, LUNR, MRK Stocks In Focus

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044

Vanda Pharmaceuticals is set to launch BYSANTI in the second half of 2026 following FDA approval for bipolar I disorder and schizophrenia, with patent protection extending until May 2044. The company also reported strong Q2 Fanapt sales growth and has several late-stage pipeline readouts …

Is West Pharmaceutical Services (WST) Undervalued After Its Run to $349.42?

West Pharmaceutical Services (WST) has seen significant share price appreciation and currently trades at $349.42, with analysts estimating a fair value of around $404, suggesting it is undervalued by approximately 13.5%. The company's growth is driven by GLP-1 exposure and plans for operational efficiencies, …

Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next

Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong second-quarter 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increase signals management's confidence in XDEMVY's commercial trajectory, though the company still faces risks associated …

ETFs Investing in Banco Macro SA Sponsored ADR Class B Stocks

This article lists ETFs that invest in Banco Macro SA Sponsored ADR Class B stocks, detailing their market value, weight, issuer, management style, and expense ratio. Key ETFs include Global X MSCI Argentina ETF (ARGT), Amplify International Enhanced Dividend Income ETF (IDVO), Investo Argentina …

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …

International Business Machines Corporation $IBM Stock Holdings Lessened by Prospera Financial Services Inc

Prospera Financial Services Inc. decreased its stake in IBM by 10.3% in Q2 2026, selling 5,070 shares and retaining 44,175 shares valued at $12.43 million. Despite this, other major institutional investors like Vanguard and State Street increased their holdings, with institutional investors collectively owning …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Empowered Funds LLC Buys 25,775 Shares of MACOM Technology Solutions Holdings, Inc. $MTSI

Empowered Funds LLC significantly increased its stake in MACOM Technology Solutions Holdings, Inc. (MTSI) by 282.5% in Q1 2026, acquiring an additional 25,775 shares, bringing its total to 34,898 shares valued at $7.75 million. This comes as institutional investors and hedge funds own a …

Bank of America Corp DE Purchases 240,902 Shares of PennyMac Financial Services, Inc. $PFSI

Bank of America Corp DE significantly increased its stake in PennyMac Financial Services (NYSE:PFSI) by 173.9% in the first quarter, acquiring an additional 240,902 shares. This brings their total holding to 379,429 shares, valued at approximately $33.2 million. Despite PennyMac missing its Q1 EPS …

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Bell Bank Increases Position in International Business Machines Corporation $IBM

Bell Bank increased its stake in International Business Machines (NYSE:IBM) by 5.1% in the second quarter, making it their 17th largest position. Several other institutional investors also adjusted their holdings in IBM, which reported earnings meeting consensus estimates but slightly missed revenue projections. Analysts …

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Does MACOM’s Q3 Profit Surge And Higher Guidance Reshape The Bull Case For MTSI?

Intuitive Machines (LUNR) Following Earnings And Defense Win Is The Growth Story Already Priced In

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

Discipline and Rules-Based Execution in MNR Response

This article from Stock Traders Daily discusses the application of discipline and rules-based execution in response to Mach Natural Resources Lp (NYSE: MNR). It highlights a neutral near and mid-term outlook with a potential long-term positive bias, noting an exceptional risk-reward short setup. The …

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions